Sangamo Therapeutics (SGMO)
NASDAQ:SGMO
Total Valuation
Sangamo Therapeutics has a market cap or net worth of $124.32M. The enterprise value is $115.69M.
Market Cap$124.32M
Enterprise Value$115.69M
Share Statistics
Sangamo Therapeutics has 414,274,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding414,274,020
Owned by Insiders1.37%
Owned by Institutions2.29%
Financial Efficiency
Sangamo Therapeutics’s return on equity (ROE) is 8.62 and return on invested capital (ROIC) is -698.43%.
Return on Equity (ROE)8.62
Return on Assets (ROA)-2.06
Return on Invested Capital (ROIC)-698.43%
Return on Capital Employed (ROCE)-7.02
Revenue Per Employee216.13K
Profits Per Employee-671.76K
Employee Count183
Asset Turnover0.66
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sangamo Therapeutics is ―. Sangamo Therapeutics’s PEG ratio is 0.09.
PE Ratio―
PS Ratio2.98
PB Ratio-8.25
Price to Fair Value-8.25
Price to FCF-1.21
Price to Operating Cash Flow-1.04
PEG Ratio0.09
Income Statement
In the last 12 months, Sangamo Therapeutics had revenue of 39.55M and earned -122.93M in profits. Earnings per share was -0.44.
Revenue39.55M
Gross Profit0.00
Operating Income-121.24M
Pretax Income-123.50M
Net Income-122.93M
EBITDA-121.24M
Earnings Per Share (EPS)-0.44
Cash Flow
In the last 12 months, operating cash flow was -97.21M and capital expenditures -102.00K, giving a free cash flow of -97.31M billion.
Operating Cash Flow-97.21M
Free Cash Flow-97.31M
Free Cash Flow per Share-0.23
Dividends & Yields
Sangamo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.31
52-Week Price Change-57.51%
50-Day Moving Average0.38
200-Day Moving Average0.49
Relative Strength Index (RSI)40.02
Average Volume (3m)7.65M
Important Dates
Sangamo Therapeutics upcoming earnings date is May 18, 2026, After Close (Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Sangamo Therapeutics as a current ratio of 0.84, with Debt / Equity ratio of -175.87%
Current Ratio0.84
Quick Ratio0.84
Debt to Market Cap0.21
Net Debt to EBITDA-0.03
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Sangamo Therapeutics has paid -568.00K in taxes.
Income Tax-568.00K
Effective Tax Rate<0.01
Enterprise Valuation
Sangamo Therapeutics EV to EBITDA ratio is -1.00, with an EV/FCF ratio of -1.25.
EV to Sales3.08
EV to EBITDA-1.00
EV to Free Cash Flow-1.25
EV to Operating Cash Flow-1.25
Balance Sheet
Sangamo Therapeutics has $20.95M in cash and marketable securities with $25.09M in debt, giving a net cash position of -$4.14M billion.
Cash & Marketable Securities$20.95M
Total Debt$25.09M
Net Cash-$4.14M
Net Cash Per Share-$0.01
Tangible Book Value Per Share-$0.05
Margins
Gross margin is 64.03%, with operating margin of -306.53%, and net profit margin of -310.81%.
Gross Margin64.03%
Operating Margin-306.53%
Pretax Margin-312.25%
Net Profit Margin-310.81%
EBITDA Margin-306.53%
EBIT Margin0.00%
Analyst Forecast
The average price target for Sangamo Therapeutics is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside1900.00% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-37.13%
EPS Growth Forecast40.47%